VCRE
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.05 | $228,246 | -$16M |
| 2026 Q1 | -3.90 | $602,000 | -$118M |
| 2025 Q4 | -5.40 | $419,000 | -$81M |
| 2025 Q3 | -0.05 | $80,725 | -$11M |
| 2025 Q2 | -4.90 | $2M | -$106M |
| 2025 Q1 | -4.80 | $892,000 | -$86M |
| 2024 Q4 |
| -0.04 |
| $461,228 |
| -$51M |
| 2024 Q3 | -0.05 | $0 | -$86M |